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A B S T R A C T
Background: Extensively drug-resistant tuberculosis (XDR-TB) has recently been identiﬁed as a major
threat to global health. XDR-TB poses a risk of higher failure rates and death during TB treatment. We
report herein the outcomes of XDR-TB in patients treated with the standardized regimen in Iran.
Patients andmethods: Between 2002 and 2006, seven patients were diagnosed with XDR-TB. All patients
were treated with the standardized second-line regimen containing cycloserine, prothionamide,
amikacin, and oﬂoxacin. First-line drugs, such as ethambutol and pyrazinamide, were added to the
regimen if drug susceptibility testing showed sensitivity to these drugs.
Results: Four (57.1%) patients were male. All seven patients were HIV-negative. The patient age range
was 22–79 years. Of the seven cases, the ﬁnal outcome was ‘cure’ in two (28.6%), ‘relapse’ in one,
‘treatment failure’ in one, and ‘death’ in two; the outcome for one patient was unknown.
Conclusion: Our study shows a poor prognosis in patients with XDR-TB. This indicates the necessity of
detecting XDR-TB cases earlier, as well as the need to gain access to more second-line agents. This is
particularly important in resource-limited settings in order to administer individualized regimens.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Approximately nine million people will get tuberculosis (TB)
annually, and more than two million TB-related deaths are
reported annually worldwide.1 Despite meticulous efforts to
control TB disease in most regions, the emergence of drug
resistance in mycobacterial strains represents a major obstacle to
attaining efﬁcient TB control. Multidrug-resistant tuberculosis
(MDR-TB) is deﬁned as resistance to at least isoniazid and
rifampin, the two most potent ﬁrst-line drugs used in the
treatment of TB. Meanwhile, extensively drug-resistant TB
(XDR-TB) has emerged as a catastrophic condition in the
management of TB. XDR-TB has recently been identiﬁed as a
major threat to global health. The problem is complicated, as XDR-
TB poses a risk of higher failure rates and death during TB
treatment, mostly due to the lack of novel drugs active against the
resistant strains.2–4
The revised deﬁnition of XDR-TB comprises resistance to
isoniazid and rifampin, plus resistance to any ﬂuoroquinolone and* Corresponding author. Tel.: +98 21 22296362.
E-mail address: tabarsi@nritld.ac.ir (P. Tabarsi).
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amikacin, capreomycin, and kanamycin.5–7 However, innumerable
questions remain regarding the management of XDR-TB, including
those concerning appropriate therapy, novel medications, and
treatment outcomes and prognosis. To-date little information has
been reported worldwide on the outcome of treatment in XDR-TB
cases. Since the World Health Organization (WHO) guidelines
recommend the use of at least four active drugs in thosewithMDR-
TB, XDR-TB may appear to be untreatable by international
standards. Accordingly, the available data show a high mortality
rate associated with XDR-TB.8 Nevertheless, in some studies ‘cure’
or ‘treatment completion’ has been reported to be as high as 31–
61% in XDR-TB cases.9
We report herein the outcome of the ﬁrst cohort of XDR-TB
patients in Iran.
2. Methods and results
Second-line drugs for the treatment of MDR-TB have been
available in Iran since 2002.10,11 According to Iran’s National TB
Treatment Protocol, all TB patients with WHO regimen category I
(CAT I) and category II (CAT II) failures are referred to our center for
evaluation and treatment of MDR-TB.ses. Published by Elsevier Ltd. All rights reserved.
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Tuberculosis and Lung Disease (NRITLD) at Masih Daneshvari
Hospital, the sole national referral center for TB in Iran, which
includes the National Mycobacteriologic Reference Laboratory.
All patients with documented MDR-TB based on drug suscept-
ibility testing (DST) are treated with the standard second-line
regimen, consisting of cycloserine, prothionamide, amikacin, and
oﬂoxacin. First-line drugs such as ethambutol and pyrazinamide
are added to the regimen if the DST shows sensitivity to these
drugs. For those patients with MDR-TB, second-line drug suscept-
ibility tests are performed as well.
Between 2002 and 2006, 105 patients with suspected MDR-TB
were identiﬁed at Masih Daneshvari Hospital in Tehran, Iran. Of
these patients, seven (6.6%) were diagnosed with XDR-TB; their
DST results became available later in the course of therapy. A brief
description of each case follows.
3. Case 1
A 22-year-old man presented to our center with a productive
cough, fever, nocturnal perspiration, and weight loss since 2002.
He was originally from the neighboring country of the Republic of
Azerbaijan. The patient did not have any history of contact or
exposure to suspected TB patients, nor did he have a history of
other previous illnesses or any underlying diseases. He was
negative for HIV infection.
He had been receiving irregular CAT I and CAT II treatment
regimens for his TB and was referred to our center as a CAT II
treatment failure. DST showed resistance to all ﬁrst-line anti-TB
drugs. Surprisingly, later DST for second-line agents demonstrated
resistance to all the second-line drugs except for cycloserine and
ethionamide (Table 1).
When ﬁrst seen at our center as a likely MDR-TB case, he was
hospitalized and then underwent anti-TB treatment with the
standardized regimen containing cycloserine, amikacin, oﬂoxacin,
and prothionamide. Treatment started in August 2004 and lasted
for a complete course of 24 months. His cultures ﬁrst turned
negative after 4 months of treatment. Amikacin was administered
for 7 months after his sputum turned negative. He did not develop
any adverse effects attributed to the anti-TB drugs during the
course of treatment.
Having completed the treatment course, ﬁve further sputum
smears and cultures for Mycobacterium tuberculosis (MTB) were
negative. In accordance with the negative mycobacteriologic
studies, along with radiographic improvement on chest X-ray,
his treatment outcome was categorized as ‘cure’. He showed no
symptoms or signs suggestive of recurrence of the infection at the
next two consecutive annual follow-up visits.
4. Case 2
A 63-year-oldwoman presented to our centerwith a productive
cough since 2004. Shewas Iranian and did not have any underlyingTable 1
Drug susceptibility tests and outcomes of patients with XDR-TB in Iran
Age (years) Sex Nation OFX CIP CS A
1 22 M Azerbaijan R R S R
2 63 F Iran R R S R
3 63 M Iran R R R R
4 55 F Afghanistan R R S R
5 64 M Iran R R S R
6a 79 F Iran R R R R
7 24 M Azerbaijan R R R R
M, male; F, female; S, sensitive; R, resistant; OFX, oﬂoxacin; CIP, ciproﬂoxacin; CS, cyclo
acid; CM, capreomycin; PZA, pyrazinamide; EMB, ethambutol.
a Primary XDR-TB.disease or previous illnesses. Serologic testing showed that shewas
negative for HIV. She had received the CAT I regimen, and due to its
failure, CAT II for 8 months. DST results showed resistance to all
ﬁrst-line anti-TB drugs. Similar to case 1, DST results for the
second-line agents showed resistance to all second-line drugs,
except for cycloserine (Table 1).
In April 2006, she was hospitalized at our center as a CAT II
treatment failure case. Similarly to case 1, she received the
standardized regimen and underwent treatment for 24 months.
Her culture ﬁrst turned negative after 6 months of treatment. She
received 6 months of amikacin after her sputum became negative.
The patient did not develop any adverse drug reactions during this
treatment.
As a result of ﬁve negative sputum smears and cultures in the
last 12 months of treatment, she was categorized as ‘cure’ for
treatment outcome. At her one-year follow-up visit, she did not
have any complaints or signs suggestive of TB recurrence.
5. Case 3
A 65-year-old Iranian man presented to our center with a
productive cough and chest pain since 2001. He was negative for
HIV and was otherwise healthy. He had received three courses of
therapy (CAT I twice for 6 months and CAT II for 8 months)
irregularly over the past year.
According to the DST results, he was resistant to all ﬁrst-line
anti-TB drugs. Also, further DST showed resistance to all second-
line anti-TB drugs, identifying extensive-drug resistance
(Table 1).
His treatment was started in February 2003 and he received the
standard regimen, with amikacin for 10 months. After 2 years,
because of two occurrences of negative sputum smear and culture
at the end of the second year of treatment, his treatment was
terminated and he was categorized as ‘cure’. Unfortunately, 6
months after treatment termination, his general condition
deteriorated and the disease manifestations were aggravated. In
further evaluations, his sputum smear and culture became positive
again.
Due to limitations in access to diverse second-line anti-TB
agents in Iran, the patient was retreated with the same standard
regimen. Having undergone more than a year of his retreatment
course, his sputum smear and culture has, to-date, been
repeatedly positive. Using DNA ﬁngerprinting, the strain of TB
responsible for his recent complaintswas identiﬁed as the same as
the ﬁrst infecting strain. Thus, he has been categorized as a
‘relapse’ case.
6. Case 4
A 55-year-old female patient presented to our center with a
productive cough, fever, chills, dyspnea, and weight loss, with a
history of TB since 2001. She was referred to our center regarding
her history of irregular treatment with CAT I and CAT II regimens.M KM ETO PAS CM PZA EMB Outcome
R S R R R R Cure
R R R R R R Cure
R R R R R R Relapse
R R S R R S Failure
R S S R S S Death
S R S R R R Death
R R R R R R Unknown
serine; AM, amikacin; KM, kanamycin; ETO, ethionamide; PAS, para-aminosalicylic
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Afghanistan. She did not report any previous illnesses or under-
lying conditions. Her HIV test was negative.
Cultures were resistant to all ﬁrst-line agents except for
ethambutol, to which her DST showed sensitivity. DST showed
resistance to all second-line agents with the exception of
cycloserine and para-aminosalicylic acid (PAS) (Table 1).
Treatmentwith the standard regimenwas started in April 2006.
Despite receiving treatment for more than 18 months, her sputum
smears and cultures have remained positive. Therefore, she is
considered a treatment ‘failure’ case.
7. Case 5
A 64-year-old man presented to our center with a productive
cough, hemoptysis, anorexia, and weight loss since 1999. He was
Iranian and had no history of underlying problems. He was
negative for HIV. He had received one course of 6-month anti-TB
treatment and was referred to our center because of CAT I
treatment failure.
DST for the ﬁrst-line agents showed resistance to isoniazid,
rifampin, and streptomycin, but sensitivity to ethambutol and
pyrazinamide. DST for second-line agents revealed resistance to
oﬂoxacin, ciproﬂoxacin, amikacin, kanamycin and capreomycin,
while showing sensitivity to other second-line agents such as
cycloserine, ethionamide, and PAS (Table 1).
From February 2004, he received the standard regimen,
including ethambutol and pyrazinamide. Amikacin was adminis-
tered for 7 months. During the course of treatment he developed
neurologic adverse effects as a result of the cycloserine, hence his
cycloserine was discontinued. Seven months after treatment was
initiated, his condition became aggravated and he died due to
respiratory arrest.
8. Case 6
A79-year-oldwoman presented to our centerwith a productive
cough and dyspnea. She was Iranian and lived in a day-care
residence. She had no history of prior TB or being treated for such a
disease.
DST showed resistance to all ﬁrst-line drugs. DST for second-
line drugs showed sensitivity to kanamycin and capreomycin only,
and showed resistance to all other second-line agents (Table 1).
She was categorized as a primary XDR-TB case, presenting for the
ﬁrst time to our center.
She was started on the standard regimen of second-line agents.
However, one week after treatment initiation, she developed acute
respiratory distress syndrome (ARDS) and died.
9. Case 7
A 24-year-old man who had come from Republic of Azerbaijan,
presented to our center with a productive cough, nocturnal
perspiration, and weight loss. He had no underlying problem and
was referred because of CAT I treatment failure. DST for his ﬁrst-
line agents showed resistance to all the drugs. Moreover, DST also
showed resistance to all second-line drugs (Table 1).
During the course of treatment and because of his personal
consent, the patient was transferred to Azerbaijan for treatment
continuation. We have no data on his later condition and hence his
ﬁnal outcome is unknown.
10. Discussion
Of the 105 patients seen between 2002 and 2006, seven (6.6%)
were diagnosed with XDR-TB. Four (57.1%) patients were male. Allseven patients were HIV-negative. The mean age of the patients
was 52.85  21.61 years (range 22–79 years).
One of the seven patients was diagnosed as having primary
XDR-TB, with no history of previous treatment and no known close
contact. Of the remaining six patients, all had a history of previous
anti-TB treatment.
Our data show that XDR-TB developed predominantly in cases
who had received prior anti-TB medication. This mandates further
consideration of anti-TB medication as a potential cause in the
creation of the more difﬁcult-to-treat drug-resistant strains (i.e.,
XDR-TB). The most important factor in controlling the develop-
ment of drug-resistant TB is the completion of treatment, as poor
compliance has been identiﬁed as the main cause; this may also be
true in our setting.7,12
The currently available data from a variety of studies in
different settings indicate that approximately 4–19% of assumed
MDR-TB isolates are in fact XDR-TB.13 This proportion was 6.7% in
our study.
All patientswere treatedwith the aforementioned standardized
second-line regimen, as individualized treatment could not be
administered due to the unavailability of other second-line agents
in Iran.
As MDR-TB persists as a growing problem, XDR-TB is also
becoming more prevalent among infected patients.2,7 MDR-TB is
now found to have different outcomes in various settings.
According to our recent report on MDR-TB treatment outcomes
with the standardized regimen, approximately 67% of cases reach a
successful outcome.11,14 Although there has been little information
reported regarding the outcome of treatment in XDR-TB cases,
successful cases are few. In addition, co-infection with HIV greatly
increases the chances of death.8,15 Since the seven patients in this
study were not infected with HIV, we were able to assess more
directly the treatment outcome of XDR-TB in patients with fewer
confounding factors.
Our study shows a poor prognosis in patients with XDR-TB,
since only two patients out of the seven were successfully treated
without relapse. Failure and/or death appear to be more likely
outcomes, even with the standard second-line drug regimen.
Similar results are being reported worldwide.7,16
However, data are scarce on whether, for XDR-TB cases, the
standardized regimen (either the same as that used for MDR-TB
or another standardized regimen different from the former)
should be used or whether one should directly address the issue
with individualized regimens speciﬁed for each case according
to his/her second-line DST results. Our study ﬁndings show that
there was no obvious correlation between the drugs to which a
case was resistant and his/her ﬁnal treatment outcome. The
small number of cases in our study may have inﬂuenced these
results.
In a study performed in the USA, 17 out of 922 (2%) MDR-TB
patients were identiﬁed as having XDR-TB between the years 2000
and 2006. Six (35%) patients were noted as successfully cured. The
study also showed that two (12%) patients died during treatment;
the outcomes of nine (52.9%) patients were not reported. As
compared to the US study, our results show a slightly lower cure
rate (28.6%) and a higher death rate (28.6%). The US study also
showed a high rate of primary XDR-TB: 14 (82%) in the US
compared to one (14.3%) in our study.15
XDR-TB has proven to be difﬁcult to cure. Further studies on
larger sample sizes should be carried out in order to better assess
the likelihood of survival.
11. Conclusions
The treatment of XDR-TB is a complex issue. There have been
few recommendations for the treatment of XDR-TB, and amongst
M.R. Masjedi et al. / International Journal of Infectious Diseases 14 (2010) e399–e402e402these, no favorable results have been reported. Likewise, our study
showed unfavorable results with standardized regimens.
Early detection of infection and access to affordable drugs
worldwide will help prevent the progression of this disease. Also,
the development of novel and more rapid DST methods is
necessary, and these should be made widely available in order
to detect XDR-TB cases earlier.
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